Current filters:


Bayer gains two orphan drug designations for riociguat

Bayer gains two orphan drug designations for riociguat


Bayer’s investigational drug riociguat has been granted two orphan drug designations by the US Food…

BayerNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonaryriociguat

Bayer's PAH/CTEPH drug gets unanimous backing from FDA advisory panel


In what was largely expected following this week's briefing papers from US Food and Drug Administration…

AdempasBayerNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonaryriociguat

FDA staffers back riociguat approval, but with modified dose


On Tuesday (August 6), the US Food and Drug Administration's Renal Drugs Advisory Committee will discuss…

ActelionAdempasBayerNorth AmericaOpsumitPharmaceuticalRegulationRespiratory and PulmonaryriociguatTracleer

US pulmonologists views on PAH prescribing options


US pulmonologists surveyed by health care advisory firm Decision Resources consider a drug's effect on…

ActelionBayerMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonaryriociguat

Bayer's PAH drug candidate riociguat gets US priority review; Sativex rescheduled in UK


The US Food and Drug Administration has granted priority review to German drug major Bayer's (BAYN: DE)…

BayerEuropeGW PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryriociguatSativex

Bayer presents strong Ph III riociguat data, which met primary endpoint in PAH


Germany's Bayer (BAYN: DE) HealthCare unit yesterday announced positive data for riociguat from the pivotal…

BayerPharmaceuticalResearchRespiratory and Pulmonaryriociguat

Back to top